Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines
- 1 April 2014
- journal article
- review article
- Published by Elsevier BV in Cytotherapy
- Vol. 16 (4), 427-439
- https://doi.org/10.1016/j.jcyt.2013.09.008
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletionNature Medicine, 2013
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- Induction of T cell anergy: integration of environmental cues and infectious toleranceCurrent Opinion in Immunology, 2010
- Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumorsSeminars in Immunology, 2010
- Pattern Recognition Receptors and InflammationCell, 2010
- Human Dendritic Cells Induce the Differentiation of Interleukin-21-Producing T Follicular Helper-like Cells through Interleukin-12Immunity, 2009
- A systematic review of humoral immune responses against tumor antigensCancer Immunology, Immunotherapy, 2009
- The capacity of the TNF family members 4‐1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cellsEuropean Journal of Immunology, 2008
- Functional Specializations of Human Epidermal Langerhans Cells and CD14+ Dermal Dendritic CellsImmunity, 2008
- DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27Nature Immunology, 2007